NDC product
ESOMEPRAZOLE MAGNESIUM
NDC 16571-880 · Rising Pharma Holdings, Inc.
Key facts
| Product NDC | 16571-880 |
|---|---|
| Proprietary name | ESOMEPRAZOLE MAGNESIUM |
| Nonproprietary name | ESOMEPRAZOLE MAGNESIUM |
| Substances | ESOMEPRAZOLE MAGNESIUM |
| Dosage form | CAPSULE, DELAYED RELEASE |
| Route | ORAL |
| Labeler | Rising Pharma Holdings, Inc. |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA216349 |
| Pharmacologic classes | Cytochrome P450 2C19 Inhibitors [MoA], Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA] |
| Marketing start | Dec 1, 2022 |
| Marketing end | May 11, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory